AURA News and Press, Aura Biosciences Inc. From 11/30/22

Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the launch of an underwritten public offering of its common stock. All shar...

Aurora set for major expansion after SET debut, first for jewel retail biz BANGKOK, Nov 29, 2022 - (ACN Newswire) - Aurora Design PCL (SET: AURA), one of Thailand's leaders in gold jewelry retail business, diamond jewelry and gems, is going ahead with its planned expansion aft...

Aura Biosciences press release ( NASDAQ: AURA ): Q3 GAAP EPS of -$0.54 misses by $0.03 . As of September 30, 2022, Aura had cash and cash equivalents and marketable securities totaling $111.5 million. Aura believes its current cash and cash equivalents and marketable s...

Announced the Global Phase 3 Trial Design with Suprachoroidal Route of Administration of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma First Patient Dosed in the Phase 1 Study Evaluating Belzupacap Sarotalocan for the Treatment of Non-Muscle Invasive Bladder Cancer ...

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that it has initiated startup activities for the global Phase 3 trial. After presenting p...

- Favorable Safety Profiles and Encouraging Efficacy Data Reported in Clinical Trials in the Suprachoroidal Space (SCS ® ) Across Multiple Therapeutic Areas using Clearside’s SCS Microinjector ® - - SCS Microinjector ® Feat...

Aura Biosciences, Inc. ( NASDAQ: AURA ) dropped ~16% on Monday after the oncology-focused biotech announced interim data for eye cancer candidate belzupacap sarotalocan from a Phase 2 trial for patients with early-stage choroidal melanoma. The trial, designed to evaluate...

Aura to Host Virtual Investor Day at 11:30 a.m. Eastern Time Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that interim Pha...

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the first patient has been dosed in a Phase 1 study evaluating belzupacap sarotalocan, th...

Company to Host Virtual Investor Day with Ocular Oncology Experts on Monday, October 3, 2022, at 11:30 a.m. Eastern Time Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for mu...